Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial.

Cox, C; Fry, K; Sivakumaran, Y; Spelman, L; Khosrotehrani, K

Cox, C; Fry, K; Sivakumaran, Y; Spelman, L; Khosrotehrani, K.

Afiliação

Cox C; The University of Queensland, Frazer Institute, Dermatology Research Centre, Experimental Dermatology Group, Brisbane, Queensland, Australia.
Fry K; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Sivakumaran Y; Queensland Institute of Dermatology, Brisbane, Queensland, Australia.
Spelman L; The University of Queensland, Frazer Institute, Dermatology Research Centre, Experimental Dermatology Group, Brisbane, Queensland, Australia.
Khosrotehrani K; Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

J Eur Acad Dermatol Venereol ; 2023 Mar 13.

Article em En | MEDLINE | ID: mdl-36914411

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google